Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China
Yi Qian Zhang, Jun Xia Wu, Hai Yan Tu, Zhao Ting Ren, Pei Pei Chen, Jia Xiu Zhang, Kun Ling Ma
Department of Nephrology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
DOI 10.5414/CN111956
Abstract
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are now recommended as first-line therapies for chronic kidney disease. However, real-world evidence on henagliflozin, China’s first-developed SGLT2 inhibitor, for treating IgA nephropathy (IgAN) is lacking. This study explored the real-world efficacy and safety of henagliflozin in Chinese IgAN patients. Materials and methods: This study retrospectively reviewed 48 IgAN patients on henagliflozin for 12 weeks. The primary outcome was the urinary albumin-to-creatinine ratio (UACR). Secondary outcomes included estimated glomerular filtration rate (eGFR), serum creatinine (Scr), uric acid (UA), and albumin (Alb). Adverse events (AEs) were also recorded. Results: Henagliflozin induced a significant reduction in UACR between baseline and week 12 (227.26; IQR, 90.13 – 677.85 vs. 153.06; IQR, 24.68 – 401.76 mg/g; p < 0.001), with a median decrease of 47.9%. Clinical response, defined as a ≥ 30% decrease in UACR, was achieved in 64.6% of patients by week 12. The UA levels also decreased markedly (p < 0.001). The eGFR declined until week 8 (p ≤ 0.015) but returned to near-baseline level by week 12 (p = 0.055). Scr increased over time (p = 0.005), and Alb improved until week 8 (p ≤ 0.007) and then plateaued at week 12 (p = 0.45). AEs included urinary tract infections in 5 patients, Scr increase of ≥ 50% in 1, and hyperkalemia in 1. Conclusion: Henagliflozin demonstrated significant albuminuria- and UA-lowering effects over 12 weeks in Chinese IgAN patients. With renal-metabolic benefits and favorable safety, henagliflozin is emerging as an encouraging therapeutic option for IgAN.
Author Details
Authors
Departments
- Department of Nephrology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Address
Kun Ling Ma, PhD, Department of Nephrology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China
Email:
[email protected]
Citation
Yi Qian Zhang, Jun Xia Wu, Hai Yan Tu, Zhao Ting Ren, Pei Pei Chen, Jia Xiu Zhang, and Kun Ling Ma. Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China
. ; : 0-9. doi: 10.5414/CN111956.
